An autoimmune background is suspected for Doberman hepatitis (DH). It is based on the finding of mononuclear cell infiltrates in the liver, strong female bias, association to the homozygous risk factor dog leucocyte antigen (DLA) allele DRB1*00601 and aberrant major histocompatibility complex (MHC) class II expression on hepatocytes that correlates with the degree of inflammation in the liver. The aim of this study was to search for autoantibodies against liverrelated antigens associated with DH. Twenty-five Dobermans with subclinical DH (SDH), 13 that clinically manifest DH (CDH) and 17 healthy controls were studied. Immunoblotting analysis detected specific antibodies in the DH sera. By mass spectrometry the targets were identified as liver-related enzymes glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and alcohol dehydrogenase (ADH). Using ELISA, anti-GAPDH IgG was detected in 36% (9/25) of SDH dogs and 69.2% (9/13) of the CDH dogs compared to healthy controls (0/17) (P < 0.0005). Anti-ADH IgG was detected in 72% (18/25) of SDH dogs and 76.9% (10/13) of CDH dogs and only in one (1/17) control (P < 0.0005). The finding of novel autoantigens, GAPDH and ADH strengthen the hypothesis that DH is an autoimmune disease of the liver. These findings suggest that DH could be diagnosed by screening for autoantibodies against the defined antigens.
Introduction
Autoimmunity as a cause for Doberman hepatitis (DH) has been proposed because of mononuclear cell infiltrates in the liver, strong female bias and an abnormal expression of major histocompatibility complex (MHC) class II antigens on hepatocytes that correlates with the degree of inflammation in the liver [1] . Furthermore, all dogs with DH are homozygous for the DLA-DRB1*00601 risk allele [2] . A persistent increase in the alanine aminotransferase (ALT) activity [3] and an increase in hepatic copper levels have been detected [4] [5] [6] . DH seems to be a complex disorder involving both genetic risk factors and environmental triggers [2] . However, the underlying causes and disease mechanisms are still unknown.
B and T cells are normally selected and controlled in a way that they are not activated against the body 0 s autoantigens. In autoimmune disease, this type of selftolerance may become broken, and autologous molecules can become targets for the adaptive immune system. Thereby, B cells may start producing autoantibodies against self-antigens. In many human autoimmune diseases, specific autoantibodies have been detected are being used for disease diagnostics. Discovering autoantibodies in a disease speaks in favour of an autoimmune aetiology. It is common that several different autoantibodies are found in a single disease. For example, in autoimmune hepatitis type I (AIH-1) antibodies against catalase, alpha-enolase, cathepsin G, lactoferrin, actin and high mobility group non-histone chromosomal proteins have been detected [7] . The origins and mechanisms of autoimmunity are difficult to study in humans. Therefore, equivalent natural diseases in animals may provide better opportunities for studies into the aetiology of autoimmunity.
The domestic dog, Canis lupus familiaris, has many inherited diseases in close analogy with human diseases [8] . However, autoimmune liver diseases have not yet been documented in dogs. In humans, the main three types of autoimmune liver diseases are autoimmune hepatitis (AIH), primary biliary cholangitis (previously called primary biliary cirrhosis) and primary sclerosing cholangitis. The International Autoimmune Hepatitis Group has provided inclusion and exclusion criteria for the diagnosis of AIH. Autoantibodies make an important part of the inclusion characteristics and provide a tool for differentiating AIH from other forms of chronic hepatitis in humans. Depending on the autoantibody patterns produced, AIH is also subdivided into AIH-1 and AIH-2.
The tentative diagnosis for DH in CDH dogs is based on persistently elevated ALT level and clinical signs of liver failure. The accurate diagnosis is based on histological findings demonstrating mononuclear cell infiltration in the parenchymal and portal areas of the liver [9] and an elevated copper content in the liver [6] . Because abnormally elevated liver enzymes and clinical signs are not exclusive to DH, the discovery of serologic markers, like autoantibodies, would improve the diagnostics.
The purpose of the present case-control study was to search for and analyse autoantibodies against liver-related antigens in DH. Specific antibodies would elucidate the pathogenetic mechanisms of the disease, improve the disease diagnostics, and provide grounds for the development of novel therapies.
Material and Methods
Study material. Serum samples from 25 Doberman patients with subclinical hepatitis (SDH) (20 females and five males) and 13 Dobermans suffering from clinical DH (CDH) (11 females and two males) were obtained. Also, nine follow-up samples were collected from SDH dogs, with a period ranging from seven months to four years. DH was suspected in Dobermans with biochemical or clinical evidence of liver disease. The mean ALT concentration was 758.8 U/L (range, 256-1575 U/L) in the SDH group and 837.4 (range, 496-1157 U/L) in the CDH group (reference range 18-77 U/L). The mean alkaline phophatase concentration in the SDH group was 581.1 U/L (range, 134-1797 U/L) and 1637.4 U/L (range 403-5347 U/L) in the CDH group (reference range 33-215 U/L). The definitive diagnosis of DH was confirmed by a liver biopsy showing mononuclear cell infiltration in the parenchymal and portal areas of the liver, various degrees of increased fibrous tissue and necrosis by haematoxylin and eosin staining. Six SDH dogs had slight fibrosis and in this group, mild bridging necrosis was noted in five dogs and one dog had apoptotic cells multifocally. CDH dogs presented with moderate-tomarked fibrosis and moderate-to-massive necrosis. Positive copper staining was observed in all DH dogs with rubeanic acid stain. The copper content was assessed on a scale 0-5 with a classification previously described by [4] . In the SDH group, three dogs were grade 1, three dogs grade 1-2, nine dogs grade 2, six dogs grade 2-3 and four dogs grade 3. In the CDH group, three dogs were grade 1, eight dogs grade 2-3, one dog grade 3 and one dog grade 4. The presence of copper was associated with inflammation focally in the centrilobular region in SDH dogs. In CDH dogs, copper was mainly associated with inflammation in periportal and bridging necrosis areas. Quantification of copper was available for 11 SDH dogs with a median of 792 lg/g dry weight liver (dwl) (range 430-1886 lg/g dwl) and seven CDH dogs with a median of 1490 lg/g dwl (range 630-2430 lg/g dwl).
Eleven SDH dogs were euthanized for reasons other than DH, and the post-mortem liver histopathology was consistent with DH. The samples were collected during 1981-2010 and stored at À20°C until analysis. Samples were thawed and analysed the same day. The median age of dogs at diagnosis in the SDH group was 4.9 (range, 1.9-8.6) years and 6.2 (range, 2.5-10.3) years in the CDH group.
The control group comprised of 17 healthy Dobermans (ten females and seven males). These Dobermans underwent a thorough physical examination, haematological and serum biochemical testing and urinalysis. The ALT and alkaline phosphatase concentrations were within the reference range in all control dogs, and the dogs did not show signs of liver failure. Histopathological analysis for confirmation of the absence of DH was performedon four of the 17 control dogs at the clinical University Small Animal Hospital, Faculty of Veterinary Medicine, Helsinki, Finland. The median age of the control dogs was 8.2 (range, 2.7-13) years.
This study was approved by the National Ethics Committee for Animal Experiments in Finland (Ethical permit ESLHÀ2009À08997/YmÀ23). All study dogs were client-owned Finnish Dobermans with a written consent for participation from the owners. At presentation, the dogs did not receive any immunosuppressive medication.
Methods. In this case-control study, Western blot (WB) assays were first used to determine the possible presence of autoantibodies in DH dog sera towards dog liver proteins. Secondly, an immunoprecipitation method was applied for isolating the possible protein autoantigens from liver tissue. Mass spectrometry and proteomic analysis were used for protein identification, and finally, autoantibody concentrations for the identified autoantigens were assessed by an enzyme immunoassay (ELISA).
Detection of autoantibodies in dog sera towards liver proteins by WB. Immunoblotting was used to detect which liver protein bands were recognized by antibodies in the sera of patients with DH. Liver lysate, obtained from a patient with subclinical DH and euthanized for reasons other than DH, was prepared with RIPA buffer (RadioImmunoprecipitation assay buffer, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0). The protein amounts of the lysates were analysed by the BCA protein assay (Pierce, Rockford, IL). Proteins from the liver lysates were resolved by an 8-15% gradient SDS-PAGE under reducing conditions and blotted onto a nitrocellulose membrane. The membrane was first stained with Ponceau S red for protein visualization and then cut Ó 2017 The Foundation for the Scandinavian Journal of Immunology into strips corresponding to the lanes. The strips were placed in a test tray and treated with a 5% milk/PBS/ Tween solution for 1 h at room temperature (RT) to block non-specific protein binding and subsequently incubated with dog sera diluted 1:30 in 10% PBS (1 ml per well) overnight (o/n) at +4°C. The strips were then washed multiple times with 0.05% Tween-20/PBS (PBS/Tween). Rabbit antibody against dog IgG (Bethyl Laboratories Inc. USA) was used as the primary antibody (1:10,000, 1 h RT). This step was followed by washing with PBS/Tween. The strips were further incubated with the horseradish peroxidase-conjugated goat anti-rabbit IgG secondary antibody (Jackson ImmunoResearch Laboratories Inc., USA 1:10,000; 1 h RT). After washing, protein bands were detected by enhanced chemiluminescence. As negative controls, one strip/blot was incubated with blocking buffer in the absence of serum and another one without the primary antibody. These controls were incubated in parallel with the patient samples.
Initial serum samples from ten DH (seven SDH females, one SDH male and one CDH female) and ten control Doberman samples were studied. Furthermore, we included nine follow-up samples for the SDH dogs. The assays were also reproduced as described above but with goat anti-dog IgM and IgA (Bethyl Laboratories Inc., USA) as the primary antibodies (both 1:10,000; o/n at +4°C) and donkey antigoat (Jackson ImmunoResearch Laboratories, Inc., USA) as the secondary antibody (1:10,000; 1 h RT).
Immunoprecipitation of target antigens from dog liver. An immunoprecipitation method was applied for isolating and concentrating the possible autoantigens from dog liver for use in WB with DH patient sera. An SDH liver sample was obtained from a female patient with SDH, euthanized for other reasons than DH. Serum samples from one SDH and one control dog (background control) were used for antigen capture. Sepharose beads (A and G) were first prepared for the study. The beads were washed with PBS, centrifuged and resuspended in PBS.
To allow binding of antibodies from the sera to protein A, 100 ll portions of sera were mixed with 500 ll of PBS and 150 ll of the protein A-Sepharose slurry. The mixtures were left rotating for one hour at RT, whereafter the beads were centrifuged and collected.
A lysate of the dog liver was precleared with protein A. For this, the lysate was first centrifuged, and the supernatant was collected. 100 ll of the supernatant was mixed with 500 ll of PBS and 150 ll of dog serum treated protein A-Sepharose slurry. This mixture was left rotating for two hours. The mixture was centrifuged and the supernatant was collected for later use. The immunoprecipitation pellets were subjected to mass spectrometry.
For binding of goat anti-dog IgA to protein G-Sepharose, 150 ll of protein G-Sepharose slurry was mixed with 500 ll PBS and 25 ll of goat anti-dog IgA. A one-hour rotation at RT followed. The beads were centrifuged and then washed with PBS. The beads were then mixed with the earlier precleared serum for the formation of dog IgA beads. The precleared liver lysate was mixed with dog IgA beads and left rotating o/n at +4°C.
Mass spectrometry for proteomics. Because of the apparent reactivity of DH sera with two target autoantigens, proteomic analysis was used for their identification. The IP samples were mixed with Laemmli sample buffer with 2-mercaptoethanol to a dilution of 1/4, heated at 95°C for 5 min and run on a precast tricine gel. The gel was stained with silver. The bands of interest (reacting with SDH but not with control sera) were dissected and treated with trypsin. The subsequent peptide mixtures were analysed by mass spectrometry. This method was used as previously described and suggested for disease-associated protein identification studies [10] . Mass spectrometry analyses for protein profiling were performed at the Protein Chemistry and Proteomics Unit of the University of Helsinki, Finland.
ELISA for serum antibodies to GAPDH and ADH. The levels of autoantibodies in the sera of 38 patients (25 SDH and 13 CDH dogs) and 17 healthy controls were determined using ELISA. First, Maxisorp microtiter plates (Nunc, Denmark) were coated with GAPDH or ADH (Sigma, Germany) at 1 lg/ml in carbonate buffer (pH 9.6). With a volume of 60 ll per well, the plates were incubated o/n at +4°C. After washing with PBS/Tween five times, the wells were incubated for 1 h at RT with patient or control sera, all in duplicate (at a dilution at 1:600 in PBS) followed by washing. The wells were incubated for 1 h at RT with rabbit anti-dog IgG as the primary antibody (1:5000) in PBS with 1% BSA (PBS/BSA). After removal of the primary antibody, the wells were washed with PBS/ Tween. A 1-h RT incubation followed with HRPconjugated goat anti-rabbit IgG antibody at a dilution of 1:2000 in PBS/BSA. After washing, a visible colour reaction was observed by adding 100 ll of 8 mg OPD (ophenylenediamine dihydrochloride, Dako, Denmark) diluted in 12 ml milliQ water and five ll of peroxides 30%. The reaction was terminated by 100 ll of 1 M H 2 SO 4 . The absorbance was read at a wavelength 492 nm.
One GAPDH and ADH reactive DH sample were used as a positive control sample and put to the same location on each plate. For negative controls, the patient sera or the primary antibodies were omitted. The sample IgG antibodies against GAPDH and ADH were adjusted towards these designated control samples and classified as positive results using a cut-off value. The cut-off value was based on the distribution of the results of the healthy controls and calculated as mean absorbance value of the healthy control subjects + 2SD. This method relies on the normality of the underlying variable. All the measurements were repeated twice. The assay was also reproduced as described above but with goat anti-dog IgA (Bethyl Laboratories Inc., USA) as the primary antibody and HRP-conjugated donkey anti-goat IgG (Jackson ImmunoResearch Laboratories, Inc., USA) as the secondary antibody.
Statistical analysis. Statistical analyses were performed with a statistical programme (PASW 18.0 software for Windows; SPSS, Inc., Beijing, China) and the statistical comparisons between groups were made using student 0 s t-test, and the differences in autoantibody frequencies were analysed using the Fisher's exact test. The statistical significance of difference was defined as P < 0.05. The mean absorbance value for healthy control dogs +2 SD was used as a cut-off value for seropositivity. Graphical data presentation was using GraphPad Prism (GraphPad Software, CA, US). Normality was checked using Q-Q plots.
Results

Detection of autoantigens by immunoblotting
Sera from ten patients with DH and ten controls were used to detect bands representing possible autoantigens in dog liver tissue. Nine follow-up sera were additionally analysed from SDH dogs. A band of 37 kDa was detected by antibodies in five (four SDH and one CDH) initial DH case samples. The five other SDH dogs did not show reactivity. One control dog showed weak reactivity. Reactivity towards a 39 kDa band was noticed with a clear positive reaction in patient samples (four SDH and one CDH) and with a weak reaction in three samples from SDH dogs, while only one control dog showed weak reactivity ( Table 1) .
The immunoreactivity apparently increased with disease progression, when comparing the initial and follow-up samples from SDH dogs (Fig. 1) . From the initially negative samples, one SDH dog created a weak and three created a clear positive reaction against the 37 kDa band in the follow-up samples. For the 39 kDa protein, one SDH dog with an initially negative result produced later a clearly positive reaction and another a weaker positive reaction. Three samples showed initially weak reactivity, but samples taken later from the same dogs became more clearly positive.
Immunoblotting detecting IgA showed similar immunoreactivities as IgG, while IgM showed no reactivity against the liver autoantigens.
Immunoprecipitation and proteomic analysis
Using an immunoprecipitation protocol with Sepharose G beads, dog sera containing autoantibodies and a precleared liver lysate it was possible to isolate candidate antigens of the autoantibodies (Fig. 2) . Immunoglobulins precipitated from healthy control dogs served as controls and for comparison of reactivities. Proteins eluted from the beads were subjected to cleavage by trypsin and analysis by mass spectrometry. The analysis identified the 37 kDa band as glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and the 39 kDa band as alcohol dehydrogenase class pi chain precursor isoform 23 (ADH).
ELISA analysis of ADH and GAPDH autoantibodies
After identification of the target antigens, we used purified GAPDH and ADH for detection and quantification of the respective autoantibodies. IgG antibodies against GAPDH and ADH in patient sera were analysed by an in-house ELISA. After an initial test titration, antibody levels in patients with SDH (n = 25) and CDH (n = 13) as well as Table 1 Initial detection of antibodies against 37 and 39 kDa proteins in Dobermans with subclinical DH and control dogs by immunoblotting. Antibody reactivity against a band of 37 kDa was detected in five initial DH case samples (four SDH and one CDH). The reactivity was more often seen in the follow-up samples: seven samples were clearly positive and in one patient with subclinical weakly positive. One control dog showed weak reactivity (AE marks a weak but visible reaction, + a clear positive reaction). A difference in reactivity between groups was also observed for reactivity against a band of 39 kDa. Sera from three SDH dogs reacted weakly initially, five (four SDH and one CDH) more strongly, while only one control dog sample showed weak reactivity. In the follow-up samples, one SDH sample showed a weak, and eight SDH samples showed a stronger reactivity.
Band 37
Band 39
Initial Followup Initial
Followup in healthy control subjects (n = 17) were studied at a serum dilution of 1:600. For the anti-GAPDH ELISA, the mean absorbance values for the SDH Dobermans (1.64 AE 0.64, mean AE SD) and for the 13 CDH Dobermans (1.94 AE 0.59) were significantly higher than in control Dobermans (1.06 AE 0.35) (P < 0.0001) (Fig. 3) . Anti-GAPDH IgG was above the cut-off (1.76) in 69.2% (9/13, seven females and two males) of the clinical stage of DH and in 36% (9/25, eight females and one male) of the subclinical stage dogs. In total, ELISA detected serum specific IgG GAPDH antibodies in 47.4% (18/38, 15 females and three males) of dogs with either a clinical or subclinical disease. All the controls were negative for anti-GAPDH antibodies. A statistically significant association was noted between SDH and CDH for the presence of anti-GAPDH IgG, P < 0.0005. The anti-GAPDH IgG values showed no significant differences between the clinical and subclinical case groups (P = 0.08). The ELISA test for anti-GAPDH showed a sensitivity of 47.4% (95% CI from 31% to 64.2%) and a specificity of 100% (95% CI from 80.5% to 100%).
For the anti-ADH ELISA, the mean absorbance values for the CDH (1.44 AE 0.65) and for the SDH (1.35 AE 0.84) (mean AE SD) groups were significantly higher compared to the mean absorbance value of the control subjects, 0.47 AE 0.17 (P < 0.0001) (Fig. 4) . The ADH antibody value was above the cut-off (0.81) and considered positive in 76.9% (10/13, eight females and two males) of the clinical stage of DH and in 72% (18/25, 15 females and three males) of the subclinical stage. In total, ELISA detected serum-specific IgG ADH antibodies in 73.7% (28/38, 23 females and five males) of dogs with either a subclinical or clinical disease. In the healthy group, the percentage was only 5.9 (1/17). This one control subject was above the cut-off value, and the statistical tests were carried out with and without this result. The resulting outcome remained the same, even when the outlier was involved in the analysis. A statistically significant association was observed between SDH, CDH and the presence of anti-ADH IgG (P < 0.0005). No statistical differences were found between the subclinical and clinical case groups (P = 0.08). The sensitivity of anti-ADH ELISA (95% confidence interval (CI) from 56.9% to 86.6%) in patients with DH was 73.7%, and the specificity was 94.1%. (95% CI from 71.3% to 99.9%).
The immunoreactivities for IgA were similar, but weaker in ELISA for anti-GAPDH and anti-ADH (not shown). Figure 2 Identification of target antigens by immunoprecipitation. In this experiment, an antibody against IgA was used for the immunoprecipitation. A patient serum (SDH) revealed reactivity against specific antigens in a dog liver homogenate when compared to a control serum (CTRL). Two of the protein bands were identified by mass spectrometry as GAPDH (37 kDa) and ADH (39 kDa). Molecular weight markers are shown at left. Figure 3 Detection of IgG antibodies against GAPDH in patient with DH sera. Sera from patients with DH and control dogs were subjected to ELISA at a 1:600 dilution. A cut-off value (2 SD) of 1.76 is indicated with a dotted line. Antibody levels in SDH (n = 25) (mean AE SD 1.64 AE 0.64) and CDH (n = 13) Doberman sera (1.94 AE 0.59) were significantly higher than in controls (n = 17) (1.06 AE 0.35; P < 0.0001). 
Discussion
The aims of the present study were to identify liver-related autoantigens associated with DH and to analyse antibodies against them. This information would help understanding the disease pathogenesis, improve the diagnostics and provide a basis for the development of new treatment options for DH. Using immunoblotting and MS, two novel liver-associated target autoantigens could be identified as two dehydrogenase enzymes, the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and the alcohol dehydrogenase (ADH). The subsequently established ELISA revealed that SDH and CDH dogs had significantly elevated serum IgG immunoreactivity to GAPDH and ADH autoantigens compared to controls and that the disease was associated with both autoantibodies.
GAPDH is a glycolytic enzyme and crucial for all normally functioning cells [11] . Besides ATP production, GADPH participates in iron metabolism [11] , histone biosynthesis [12] and the execution of cell death under oxidative stress conditions when translocated to the nucleus [13] . Other functions include intracellular membrane trafficking [14] , receptor-mediated cell signalling [15] and maintenance of DNA integrity in oxidative stress [16] . GAPDH levels in mitochondria rise under stress conditions and regulate the permeabilization process of the proapoptotic apoptosis [17] . GAPDH has been demonstrated to exhibit these diverse properties linked to distinct cellular localizations. Anti-GAPDH IgG has been demonstrated in the cerebrospinal fluid of human patients with multiple sclerosis or systemic lupus erythematosus (SLE). In multiple sclerosis, the GAPDH autoantibodies are thought to inhibit glycolysis and promote neuroaxonal degeneration [18] . One study found anti-GAPDH autoantibodies in 47% of patients with SLE, and GAPDH was suggested to be both a nuclear and cytoplasmic target autoantigen in this disease [19] .
It has been speculated, that the autoimmune response could be towards foreign GAPDH through molecular mimicry, as this enzyme is present also on the surfaces of bacteria, viruses and parasites [19] . Anti-GADPH autoantibodies were found in Dobermans with dilated cardiomyopathy (DCM). The Doberman breed is predisposed to DCM, and the prognosis for the disease is less favourable compared to that for other breeds. An autoimmune origin for DCM has been speculated [20] . The fact that some Doberman dogs develop DCM and some DH suggest that additional factors in the development of immune disease are needed.
ADH refers to an enzyme family with each member having a specific role and function in the body according to their different forms. ADH enzymes have been found to be concentrated in the liver but are also found in the gastrointestinal tract and kidney. The major function of ADH is to catalyse reversible oxidation of endogenous alcohol produced by gut microbiota, ethanol or other alcohols from the diet or substrates associated with steroid and bile acid metabolism [21] . Autoantibodies towards ADH were found in alcohol liver disease, correlating with disease severity. Alcohol liver disease shares similarities with AIH and ADH has also been identified as one of the target antigens in AIH [22] . In dogs it has been hypothesized, that ADH participates in metabolic pathways involved in the metabolism of endogenous compounds, such as bile acids, catecholamines, serotonin, histidine retinoids, leukotrienes and arachidonic acid [23] .
Immune tolerance guarantees that the immune system learns to discriminate self from non-self. It is not known what causes the immune system to react to autoantigens. There may be one or several triggering factors that lead to a break in the immune tolerance and induction of autoantibodies. Potential factors for autoimmune responses could be molecular mimicry and cross-reactivity mechanisms for microbial antigens, impaired apoptosis, exposure of hidden antigens, lack of clearance of cell degradation products and post-translational modification of self-proteins. In molecular mimicry, an antigen is a foreign antigen (virus or bacteria) that shares structural or sequence similarities with self-peptides. The infectious antigen within the MHC class II can induce activation of naive autoreactive T cells, which recognize peptides derived from foreign and self-antigens and give rise to autoimmune disease [24] as is suspected, for example in primary biliary cholangitis [25] . Normally, macrophages can efficiently clear apoptotic cells and avoid exposure of autoantigens. Defects in the clearance of apoptotic cells participate in the chronic inflammation formation by supplying triggering autoantigens and initiating autoimmune response towards nuclear autoantigens, as has been demonstrated in SLE [26] . Posttranslationally modified (PTM) proteins are necessary for many cellular events, but sometimes PTM in self-proteins can affect antigen recognition and initiate autoimmune responses. Self-proteins can undergo PTM in inflammation, apoptosis or ageing. When these modified proteins are released from the cells, they are taken up by antigenpresenting cells (APCs). The modified peptide particles are presented by MHC class II to T and B cells that have escaped central tolerance. Autoreactive T and B cells may penetrate into tissues and promote autoimmune pathology [27] . PTM is a key feature in coeliac disease [28] .
The pathogenesis of DH is not known. This study provides evidence for an antigen-driven autoimmune process and clarifies the DH pathogenesis. Earlier, it was hypothesized that DH is mediated by autoimmune mechanisms and that in DH hepatocytes have become APCs [1] . Usually, MHC class II molecules are only present on specialized APCs like dendritic cells, B cells and macrophages. The interaction between antigen-presenting cells with antigen fragments and T lymphocytes is required for CD4 + T cell activation. Parenchymal cells, like hepatocytes, do not constitutively express MHC class II molecules. However, in response to cytokines (predominantly interferon-c; IFN-c) by the lymphocytic infiltrates, parenchymal cells may be induced to present MHC class II molecules [29] . DH hepatocytes express MHC class II molecules, and the abnormal appearance is associated with mononuclear cell infiltration and hepatocyte necrosis changes [1] . In the present study, the finding of autoantibodies against two liver-related autoantigens supports the assumption that DH hepatocytes have become APCs. It is suggested, that hepatocytes with GAPDH and ADH autoantigens associated with MHC class II molecules are introduced to autoreactive CD4 + helper T cells. The GAPDH and ADH autoantibodies in the sera of DH Dobermans indicate that CD4 + T cells have been activated and started to produce cytokines specific for type 2 helper T cells. These cytokines eventually cause B cell activation and autoantibody production against GAPDH and ADH. For this to occur, B cells specific for the antigens should exist and be involved in antigen capture and presentation to CD4 + helper T cells (Fig. 5) . We previously observed that in DH, Dobermans with two copies of allele DLA-DRB1*00601 have a nearly 15-fold elevated risk of developing the disease, compared to heterozygous dogs [2] . DLA genes encode for MHC class II molecules in the dog. DLA genes are the most important genes in genetic susceptibility to autoimmune disease, because MHC class II molecules are responsible for how an individual's T cells interact with self-antigens.
Our earlier study revealed antinuclear autoantibodies in DH and nuclear histones as the target antigens (Dyggve H, Jarva H, Spillmann T, Speeti M, Meri S submitted). The present study showed two new autoantibodies (against GAPDH and ADH) in DH. The patients with DH had different antibody patterns when combining these results. In the SDH group, 36% (9/25) had all three (antihistoneantibodies [AHA], anti-GAPDH and anti-ADH) antibodies elevated, 40% (10/25) of the dogs had AHA with anti-ADH. 16% (4/25) had only AHA and 8% (2/25) were seronegative for all three antibodies. All CDH dogs had elevated antibody titres against at least one of the antigens. The majority 53.8% (7/13) of the CDH dogs had all three serum antibodies elevated. Two dogs (15.4%, 2/13) had AHA with anti-ADH and two other dogs (15.4%, 2/13) had only AHA. One dog (7.7%, 1/13) showed only anti-GAPDH and one other dog (7.7%, 1/13) showed anti-GAPDH with anti-ADH. The SDH dogs did not have anti-GAPDH or anti-ADH alone or anti-GAPDH in combination with only anti-ADH or AHA ( Table 2) .
The diagnosis of DH is suggested to include the following criteria: a subsequent, at least threefold elevated ALT level indicating hepatocellular damage, a positive test for AHA, anti-GAPDH or anti-ADH antibodies and a compatible liver histology. Possible, the different patients with DH may have different autoantibody combinations that can be associated with disease prognosis, progression and response to therapy. Further studies are thus required, but we propose that all the three autoantibodies are tested, as there is no single autoantibody with sufficient diagnostic sensitivity and specificity for the diagnosis of DH. Dobermans with successively elevated ALT levels with anti-GAPDH, anti-ADH or AHA antibodies in serum Figure 5 The suggested key steps for production of autoantibodies against the liver cell antigens in DH. In an inflammatory situation, liver hepatocytes start expressing exceptionally MHC class II antigens. An autoantigenic peptide (from GAPDH or ADH) is presented by the MHC class II to undifferentiated CD4 + T cells (Th0 support a DH diagnosis. Screening these autoantibodies in patients with CDH could help in making the diagnosis, when taking a liver biopsy is risky. The results indicate a primary diagnostic value for the anti-GAPDH and ADH autoantibodies. Larger studies in the future should determine, whether the measurement of their levels is suitable for monitoring the progression of DH. The results of this study indicate that the autoantibodies could be used as a tool to differentiate DH from other forms of hepatitis due to other causes.
DH has been a therapeutic challenge, as the aetiology and pathogenesis have been obscure. The current treatment with corticosteroids has failed to halt the progression of DH, especially in the clinical stage of the disease. Our observation of autoantibodies associated with DH give strength to our theory of the autoimmune background and highlights the pathogenesis of the disease. Based on the suggested pathogenesis, new immunosuppressive approaches like statins or cyclosporine could be options to target and inhibit the autoimmune reaction in DH. Statins inhibit IFN-c inducible expression of MHC class II molecules and co-stimulatory molecules on APCs and prevent antigen presentation to CD4 + T cells. In humans, statins are used in autoimmune diseases like multiple sclerosis and SLE, where endothelial cells have started to express MHC class II molecules [30] . Statins are widely used in humans as a cholesterol-lowering drugs and are considered relatively safe also during long term use. Therefore, statins are a drug-of-choice for Dobermans suffering from SDH. Cyclosporine inhibits activated T cells that produce certain cytokines. Cyclosporine acts in the cytoplasm of activated T cells by forming a complex with cyclophilins. This complex further prevents calcineurin to dephosphorylate the nuclear transcription factor of activated T cells. Without dephosphorylation, the cytoplasmic nuclear transcription factor of activated T cells cannot enter the nucleus to start transcription of cytokines, like IL-2, which is necessary for initiation T cell growth and differentiation [31] .
A limitation for this study was that histopathological confirmation was not available for all the control dogs.
However, these dogs were considered healthy at presentation, and their health status was followed until 2 years after sampling with no elevation of ALT. An aspect yet to be determined is whether the autoantibodies have a causative role in the disease or whether they are a consequence of the disease process. Also it is not known, what the link between the autoimmune process and the previously detected copper accumulation is.
In summary, our results show that autoantibodies against liver-related antigens are associated with DH. These findings elucidate the DH aetiology and pathogenesis and could improve the diagnosis or verification of DH. With this aetiological background novel therapies with statins or cyclosporine could be tried to improve the prognosis of Dobermans. Whether antibodies per se have a functional consequence in DH remains to be investigated. Also, their detection warrants studies on possible cellmediated immunity against the same target antigens and peptides thereof. 
